PL1678172T3 - Związki azabicykliczne do łagodzenia bólu oraz leczenia zaburzeń centralnego układu nerwowego - Google Patents

Związki azabicykliczne do łagodzenia bólu oraz leczenia zaburzeń centralnego układu nerwowego

Info

Publication number: PL1678172T3
Authority: PL; Poland
Prior art keywords: nervous system; central nervous; system disorders; compounds; relieving pain
Prior art date: 2003-10-15

Application number

PL04795238T

Other languages

English (en)

Inventor

Scott R Breining

Balwinder S Bhatti

Gregory D Hawkins

Lan Miao

Anatoly Mazurov

Teresa Y Phillips

Craig H Miller

Original Assignee

Targacept Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-15

Filing date

2004-10-15

Publication date

2010-05-31

2004-10-15 Application filed by Targacept Inc filed Critical Targacept Inc

2010-05-31 Publication of PL1678172T3 publication Critical patent/PL1678172T3/pl

Links

150000001875 compounds Chemical class 0.000 title abstract 4
208000015114 central nervous system disease Diseases 0.000 title abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
208000035475 disorder Diseases 0.000 abstract 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
206010057852 Nicotine dependence Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
208000027089 Parkinsonian disease Diseases 0.000 abstract 1
206010034010 Parkinsonism Diseases 0.000 abstract 1
208000025569 Tobacco Use disease Diseases 0.000 abstract 1
208000000323 Tourette Syndrome Diseases 0.000 abstract 1
208000016620 Tourette disease Diseases 0.000 abstract 1
230000004075 alteration Effects 0.000 abstract 1
230000002950 deficient Effects 0.000 abstract 1
229960003638 dopamine Drugs 0.000 abstract 1
206010013663 drug dependence Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000003957 neurotransmitter release Effects 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1
208000011117 substance-related disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Hematology (AREA)
Virology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Diabetes (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)

PL04795238T 2003-10-15 2004-10-15 Związki azabicykliczne do łagodzenia bólu oraz leczenia zaburzeń centralnego układu nerwowego PL1678172T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US51169703P	2003-10-15	2003-10-15
EP04795238A EP1678172B1 (en)	2003-10-15	2004-10-15	Azabicyclic compounds for relieving pain and treating central nervous system disorders
PCT/US2004/034051 WO2005037832A2 (en)	2003-10-15	2004-10-15	Azabicycyclic compounds for relieving pain and treating central nervous system disorders

Publications (1)

Publication Number	Publication Date
PL1678172T3 true PL1678172T3 (pl)	2010-05-31

Family

ID=34465266

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04795238T PL1678172T3 (pl)	2003-10-15	2004-10-15	Związki azabicykliczne do łagodzenia bólu oraz leczenia zaburzeń centralnego układu nerwowego

Country Status (13)

Country	Link
US (4)	US7402592B2 (pl)
EP (1)	EP1678172B1 (pl)
JP (1)	JP2007533641A (pl)
AT (1)	ATE451368T1 (pl)
AU (1)	AU2004282201A1 (pl)
CA (1)	CA2539811A1 (pl)
DE (1)	DE602004024565D1 (pl)
DK (1)	DK1678172T3 (pl)
ES (1)	ES2356356T3 (pl)
PL (1)	PL1678172T3 (pl)
PT (1)	PT1678172E (pl)
SI (1)	SI1678172T1 (pl)
WO (1)	WO2005037832A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE521512C2 (sv) *	2001-06-25	2003-11-11	Niconovum Ab	Anordning för administrering av en substans till främre delen av en individs munhåla
ES2285233T3 (es)	2002-12-20	2007-11-16	Niconovum Ab	Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable.
WO2004083388A2 (en)	2003-03-14	2004-09-30	Bristol-Myers Squibb Company	Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
AU2004282201A1 (en) *	2003-10-15	2005-04-28	Targacept, Inc.	Azabicycyclic compounds for relieving pain and treating central nervous system disorders
US20080261999A1 (en) *	2005-03-04	2008-10-23	Fionna Mitchell Martin	Azabicycloalkane Derivatives Useful as Nicotinic Acetylcholine Receptor Agonists
US9402809B2 (en)	2006-03-16	2016-08-02	Niconovum Usa, Inc.	Snuff composition
WO2007149392A1 (en) *	2006-06-16	2007-12-27	University Of Kentucky	Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors
RU2313342C1 (ru) *	2006-06-26	2007-12-27	Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева"	Способ лечения болезни генерализованных тиков
GB0721178D0 (en) *	2007-10-29	2007-12-05	Glaxo Group Ltd	Chemical compounds
WO2009058120A1 (en) *	2007-11-02	2009-05-07	Sri International	Nicotinic acetylcholine receptor modulators
US8697722B2 (en)	2007-11-02	2014-04-15	Sri International	Nicotinic acetylcholine receptor modulators
US9125907B2 (en) *	2009-09-30	2015-09-08	Christopher Shaari	Use of botulinum neurotoxin to treat substance addictions
CA2787063C (en)	2010-01-11	2018-11-27	Astraea Therapeutics, Llc	Nicotinic acetylcholine receptor modulators
KR101730937B1 (ko)	2010-06-09	2017-04-27	얀센 파마슈티카 엔.브이.	베타-세크레타아제(ｂａｃｅ) 저해제로 유용한 5,6-디하이드로-2ｈ-[1,4]옥사진-3-일-아민 유도체
CN102985412A (zh)	2010-06-28	2013-03-20	詹森药业有限公司	可用于治疗阿尔茨海默病及其它形式的痴呆的3-氨基-5,6-二氢-1h-吡嗪-2-酮衍生物
BR112013004746A2 (pt) *	2010-09-02	2016-06-07	Takeda Pharmaceutical	"composto, medicamento, inibidor da produção de beta-amilóide, modulador de gama-secretase, métodos para inibir a produção de beta-amilóide, para modular gama-secretase, e para prevenir ou tratar deficiência cognitiva branda ou mal de alzheimer, e, uso do composto."
SG191097A1 (en)	2010-12-22	2013-08-30	Janssen Pharmaceutica Nv	5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
JP5853033B2 (ja)	2011-03-01	2016-02-09	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎＰｈａｒｍａｃｅｕｔｉｃａＮａａｍｌｏｚｅＶｅｎｎｏｏｔｓｃｈａｐ	β−セクレターゼ（ＢＡＣＥ）の阻害剤として有用な６，７−ジヒドロ−ピラゾロ［１，５−ａ］ピラジン−４−イルアミン誘導体
EP2683721B1 (en)	2011-03-09	2015-01-28	Janssen Pharmaceutica N.V.	3,4-DIHYDRO-PYRROLO[1,2-a]PYRAZIN-1-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
WO2014198854A1 (en)	2013-06-12	2014-12-18	Janssen Pharmaceutica Nv	4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace)
CA2912156C (en)	2013-06-12	2021-07-20	Janssen Pharmaceutica Nv	4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazin-3(2h)-one derivatives as inhibitors of beta-secretase (bace)
KR102243134B1 (ko)	2013-06-12	2021-04-22	얀센 파마슈티카 엔.브이.	베타-세크레타제(bace) 저해제로서의 4-아미노-6-페닐-5,6-디하이드로이미다조[1,5-a]피라진 유도체
MX2017008083A (es)	2014-12-18	2017-10-31	Janssen Pharmaceutica Nv	Compuestos 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2h-pirrol-5-amina inhibidores de beta-secretasa.
CN109153679B (zh) *	2015-09-04	2022-04-08	詹森药业有限公司	用于疼痛的治疗性化合物及其合成
SG11202007422QA (en)	2018-02-05	2020-09-29	Alkermes Inc	Compounds for the treatment of pain
WO2021026380A1 (en) *	2019-08-07	2021-02-11	Alkermes, Inc.	Phenyltriazole compounds for the treatment of pain
WO2021026375A1 (en) *	2019-08-07	2021-02-11	Alkermes, Inc.	Fused bicyclic compounds for the treatment of pain
WO2021026377A1 (en) *	2019-08-07	2021-02-11	Alkermes, Inc.	Lactam-containing compounds for the treatment of pain

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4965074A (en)	1985-03-05	1990-10-23	Ciba-Geigy Corporation	Method of treating memory impairment
NZ219646A (en) *	1986-03-27	1990-10-26	Merck Sharp & Dohme	Oxadiazole derivatives of azacyclics for treating cns disorders
WO1989000158A1 (en)	1987-07-02	1989-01-12	Pfizer Inc.	Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
US4922901A (en)	1988-09-08	1990-05-08	R. J. Reynolds Tobacco Company	Drug delivery articles utilizing electrical energy
US5210076A (en)	1988-09-13	1993-05-11	Berliner David L	Methods of treating Parkinson's disease using melanin
US5187166A (en)	1990-07-31	1993-02-16	Nisshin Flour Milling Co., Ltd.	Azabicyclo derivatives and their use as antiemetics
ES2153360T3 (es)	1991-05-29	2001-03-01	Abbott Lab	Compuestos de isoxazol e de isotiazol que mejoran las funciones de razonamiento.
US5212188A (en)	1992-03-02	1993-05-18	R. J. Reynolds Tabacco Company	Method for treatment of neurodegenerative diseases
US5242935A (en)	1992-03-06	1993-09-07	R. J. Reynolds Tobacco Company	Method for treatment of neurodegenerative diseases
US5227391A (en)	1992-04-10	1993-07-13	R. J. Reynolds Tobacco Company	Method for treatment of neurodegenerative diseases
IL107184A (en)	1992-10-09	1997-08-14	Abbott Lab	Heterocyclic ether compounds that enhance cognitive function
US5852041A (en)	1993-04-07	1998-12-22	Sibia Neurosciences, Inc.	Substituted pyridines useful as modulators of acethylcholine receptors
US5493026A (en)	1993-10-25	1996-02-20	Organix, Inc.	Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
IT1274018B (it)	1994-02-23	1997-07-14	Riace Ets	Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en)	1994-11-23	1996-05-29	Glaxo Inc	Quinazoline antagonists of alpha 1c adrenergic receptors
US5597919A (en)	1995-01-06	1997-01-28	Dull; Gary M.	Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5604231A (en)	1995-01-06	1997-02-18	Smith; Carr J.	Pharmaceutical compositions for prevention and treatment of ulcerative colitis
WO1996030372A1 (en)	1995-03-24	1996-10-03	Japan Tobacco Inc.	Diazabicyclo[3.3.1]nonane derivatives and intermediates thereof, medicinal use of the same, and processes for producing the same
US5585388A (en)	1995-04-07	1996-12-17	Sibia Neurosciences, Inc.	Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en)	1995-05-17	1996-12-10	Bencherif; Merouane	Pharmaceutical compositions for the treatment of central nervous system disorders
AU5383196A (en) *	1995-05-17	1996-11-29	R.J. Reynolds Tobacco Company	Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5616716A (en)	1996-01-06	1997-04-01	Dull; Gary M.	(3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv)	1996-02-23	1996-02-23	Astra Ab	Azabicyclic esters of carbamic acids useful in therapy
AT403803B (de)	1996-04-19	1998-05-25	Sanochemia Ltd	Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5663356A (en)	1996-04-23	1997-09-02	Ruecroft; Graham	Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en)	1996-05-03	1998-03-10	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
ZA9711092B (en)	1996-12-11	1999-07-22	Smithkline Beecham Corp	Novel compounds.
US5861423A (en)	1997-02-21	1999-01-19	Caldwell; William Scott	Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
EP0978280A1 (en) *	1997-04-26	2000-02-09	Sumitomo Pharmaceuticals Company, Limited	2-azabicyclo compounds
AR013184A1 (es)	1997-07-18	2000-12-13	Astrazeneca Ab	Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
ATE491689T1 (de)	1997-10-27	2011-01-15	Neurosearch As	Heteroaryl diazacycloalkane als cholinergische ligande für nikotin-acetylcholin-rezeptoren
US5952339A (en)	1998-04-02	1999-09-14	Bencherif; Merouane	Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
EP1083889B1 (en)	1998-06-01	2003-12-10	Ortho-McNeil Pharmaceutical, Inc.	Tetrahydronaphtalene compounds and their use for the treatment of neurodegenerative diseases
CA2677519A1 (en)	1998-06-16	1999-12-23	Targacept, Inc.	Aryl substituted olefinic amines and their use as cholinergic receptors agonists
US6310043B1 (en)	1998-08-07	2001-10-30	Governors Of The University Of Alberta	Treatment of bacterial infections
GB9821503D0 (en)	1998-10-02	1998-11-25	Novartis Ag	Organic compounds
GB9822945D0 (en) *	1998-10-20	1998-12-16	Isis Innovations Ltd	Epibatidine analogues
US6734215B2 (en)	1998-12-16	2004-05-11	University Of South Florida	Exo-S-mecamylamine formulation and use in treatment
SE9904176D0 (sv)	1999-11-18	1999-11-18	Astra Ab	New use
US6492386B2 (en)	2000-08-18	2002-12-10	Pharmacia & Upjohn Company	Quinuclidine-substituted aryl compounds for treatment of disease
US6479510B2 (en)	2000-08-18	2002-11-12	Pharmacia & Upjohn Company	Quinuclidine-substituted aryl compounds for treatment of disease
US6486172B2 (en)	2000-08-18	2002-11-26	Pharmacia & Upjohn Company	Quinuclidine-substituted aryl compounds for treatment of disease
WO2002017358A2 (en)	2000-08-21	2002-02-28	Pharmacia & Upjohn Company	Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
EP1311505A2 (en)	2000-08-21	2003-05-21	PHARMACIA & UPJOHN COMPANY	Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
US6599916B2 (en)	2000-08-21	2003-07-29	Pharmacia & Upjohn Company	Quinuclidine-substituted heteroaryl moieties for treatment of disease
MXPA05001726A (es)	2002-08-14	2005-05-27	Abbott Lab	Compuestos azabiciclicos son agentes activos del sistema nervioso central.
AU2004282201A1 (en)	2003-10-15	2005-04-28	Targacept, Inc.	Azabicycyclic compounds for relieving pain and treating central nervous system disorders

2004
- 2004-10-15 AU AU2004282201A patent/AU2004282201A1/en not_active Abandoned
- 2004-10-15 PT PT04795238T patent/PT1678172E/pt unknown
- 2004-10-15 PL PL04795238T patent/PL1678172T3/pl unknown
- 2004-10-15 DE DE602004024565T patent/DE602004024565D1/de not_active Expired - Lifetime
- 2004-10-15 AT AT04795238T patent/ATE451368T1/de not_active IP Right Cessation
- 2004-10-15 SI SI200431352T patent/SI1678172T1/sl unknown
- 2004-10-15 ES ES04795238T patent/ES2356356T3/es not_active Expired - Lifetime
- 2004-10-15 DK DK04795238.7T patent/DK1678172T3/da active
- 2004-10-15 WO PCT/US2004/034051 patent/WO2005037832A2/en not_active Ceased
- 2004-10-15 US US10/711,969 patent/US7402592B2/en not_active Expired - Fee Related
- 2004-10-15 CA CA002539811A patent/CA2539811A1/en not_active Abandoned
- 2004-10-15 JP JP2006535339A patent/JP2007533641A/ja active Pending
- 2004-10-15 EP EP04795238A patent/EP1678172B1/en not_active Expired - Lifetime
2008
- 2008-05-20 US US12/123,530 patent/US20080242693A1/en not_active Abandoned
2010
- 2010-01-12 US US12/685,868 patent/US20100179183A1/en not_active Abandoned
- 2010-02-26 US US12/714,014 patent/US7897611B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ATE451368T1 (de)	2009-12-15
US20080242693A1 (en)	2008-10-02
JP2007533641A (ja)	2007-11-22
US7897611B2 (en)	2011-03-01
EP1678172B1 (en)	2009-12-09
DK1678172T3 (da)	2010-04-06
SI1678172T1 (sl)	2010-04-30
DE602004024565D1 (de)	2010-01-21
US20100179183A1 (en)	2010-07-15
CA2539811A1 (en)	2005-04-28
US20050282823A1 (en)	2005-12-22
PT1678172E (pt)	2010-03-03
WO2005037832A3 (en)	2005-06-16
US20100152228A1 (en)	2010-06-17
EP1678172A2 (en)	2006-07-12
WO2005037832B1 (en)	2005-09-15
WO2005037832A2 (en)	2005-04-28
US7402592B2 (en)	2008-07-22
AU2004282201A1 (en)	2005-04-28
ES2356356T3 (es)	2011-04-07

Publication	Publication Date	Title
PL1678172T3 (pl)	2010-05-31	Związki azabicykliczne do łagodzenia bólu oraz leczenia zaburzeń centralnego układu nerwowego
WO2004108668A3 (en)	2006-07-20	Alpha-7 neuronal nicotinic receptor ligands: compositions and methods of use
IL165829A0 (en)	2006-01-15	N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
IL197890A (en)	2013-11-28	Arylvinylchloroalkylan compounds and their preparation methods and uses
DE60045427D1 (de)	2011-02-03	Bupropinmetaboliten zur Behandlung von Dementia und anderen zerebrovasckulären Erkrankungen
MY144483A (en)	2011-09-30	1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
UA83899C2 (uk)	2008-08-26	Сполуки імідазолу для лікування нейродегенеративних розладів
TW200420550A (en)	2004-10-16	Thiazole compounds for the treatment of neurodegenerative disorders
UA99309C2 (ru)	2012-08-10	Замещенные пиперидинодигидротиенопиримидины
MXPA02001306A (es)	2004-06-22	Composiciones farmaceuticas para el tratamiento de enfermedades del sistema nervioso central y otras enfermedades.
TW200531689A (en)	2005-10-01	Therapeutic agents
TW200635903A (en)	2006-10-16	Therapeutic agents
IL192287A0 (en)	2008-12-29	Pharmaceutical compositions and methods for use
IL113436A0 (en)	1995-07-31	Neurotransmitter release enhancers
PL370529A1 (pl)	2005-05-30	Zastosowanie pochodnych 2-okso-1-pirolidyny do wytwarzania leku
TW200633986A (en)	2006-10-01	Therapeutic agents
TW200509933A (en)	2005-03-16	Therapeutic agents
TW200631956A (en)	2006-09-16	Azabenzoxazoles for the treatment of CNS disorders
DE69822300D1 (de)	2004-04-15	3-pyridyl-1-azabicycloalkan-derivate zur behandlung von zns-erkrankungen
TW200728300A (en)	2007-08-01	Therapeutic agents
TW200607802A (en)	2006-03-01	3-piperidinylisochroman-5-ols as dopamine agonists
TW200510331A (en)	2005-03-16	Heteroaryl-substituted imidazole derivatives
MXPA06000193A (es)	2006-04-11	Derivados de imidazol iii.
TW200501958A (en)	2005-01-16	A therapeutic agent for treating a behavioral disorder
TW200628476A (en)	2006-08-16	Azabenzoxazoles for the treatment of CNS disorders